Comparing MindWalk (NASDAQ:HYFT) and Waters (NYSE:WAT)

MindWalk (NASDAQ:HYFT) and Waters (NYSE:WAT) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations for MindWalk and Waters, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1	1	2	1	2.60
Waters	0	6	17	1	2.79

MindWalk currently has a consensus price target of $5.00, suggesting a potential upside of 380.77%. Waters has a consensus price target of $475.48, suggesting a potential upside of 1.60%. Given MindWalk’s higher probable upside, equities research analysts plainly believe MindWalk is more favorable than Waters.

Valuation and Earnings

This table compares MindWalk and Waters”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$11.24 million	4.40	-$10.11 million	($0.26)	-4.00
Waters	$3.17 billion	14.53	$642.63 million	$4.01	116.71

Waters has higher revenue and earnings than MindWalk. MindWalk is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares MindWalk and Waters’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MindWalk	-105.11%	-133.26%	-77.78%
Waters	1.75%	9.91%	6.11%

Risk & Volatility

MindWalk has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Waters has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500.

Insider & Institutional Ownership

6.7% of MindWalk shares are owned by institutional investors. Comparatively, 94.0% of Waters shares are owned by institutional investors. 6.8% of MindWalk shares are owned by company insiders. Comparatively, 0.3% of Waters shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Waters beats MindWalk on 11 of the 13 factors compared between the two stocks.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

About Waters

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.